Dr. Mark Palmert, MD, PhD, is a graduate of the Medical Scientist (MD/PhD) Training Program at Case Western Reserve University and of the Pediatrics and Pediatric Endocrinology Training Programs at Children’s Hospital in Boston/Harvard University. From 2007 to 2018 he was Head of the Division of Endocrinology at The Hospital for Sick Children (“SickKids”) in Toronto. In 2018 he transitioned to his current role as Associate Chair of Pediatrics (Ambulatory/Outpatient Care), and in 2022 he took on an additional role as Interim Head of the Division of Immunology and Allergy. Dr. Palmert is a Professor of Pediatrics and Physiology at the University of Toronto and a Senior Associate Scientist in the Genetics and Genome Biology Program within the Hospital’s Research Institute. He currently serves as President-elect of the Pediatric Endocrine Society.
Dr. Palmert’s research career has involved a combination of clinical and laboratory-based projects that have been continuously funded since 1998 by grants from industry, private research foundations, the US National Institutes of Health, the Canadian Institutes of Health Research, and Health Canada. The main foci of his research efforts include: (1) regulation and disorders of pubertal timing, including the basis for sex differences in the age at onset of puberty as well as how genetics influences pubertal timing; (2) basis of sex differences in brain structure and function, including examination of factors such as sex hormone exposure, sex chromosomes and maternal diet that modulate brain development; and (3) how sex-related CNS differences may influence pubertal timing. In addition to these puberty related research and clinical activities, Dr. Palmert also maintains an active clinical practice in general endocrinology, diabetes, and the care of transgender youth.
- Summarize how genetic studies have enhanced understanding of the physiology of pubertal onset
- Identify key features that distinguish constitutional delay of growth and puberty from pathologic states
- Describe the utility of genetic tests in the diagnostic evaluation of delayed puberty
This seminar was delivered as a Pediatric Grand Rounds Lecture at Children’s Hospital of Philadelphia, on November 29, 2023.
The work presented in the presentations, videos, and other content on this site (“Presentations”) includes publicly available medical evidence, a consensus of medical practitioners, and/or opinions of individual practitioners that may differ from consensus opinions. These Presentations are intended only to provide general information and need to be adapted for each specific patient based on the practitioner’s professional judgment, consideration of any unique circumstances, the needs of each patient and their family, the availability of various resources at the health care institution where the patient is located, and other factors. The Presentations are not intended to constitute medical advice or treatment, nor should they be relied upon as such. The Presentations are not intended to create a doctor-patient relationship between/among The Children’s Hospital of Philadelphia, its physicians and the individual patients in question. The information contained in these Presentations are general in nature, and do not and are not intended to refer to specific patients.
CHOP, The Children’s Hospital of Philadelphia Foundation and its or their affiliates, the authors, presenters, practitioners, editors, and others associated with the creation of the Presentations (“CHOP”) are not responsible for errors or omissions in the Presentations; for any outcomes a patient might experience where a clinician reviewed one or more such Presentations in connection with providing care for that patient; and/or for any and all third party content on the site or in the Presentations. CHOP makes no warranty, expressed or implied, with respect to the currency, completeness, applicability or accuracy of the Presentations. Application of the information in or to a particular situation remains the professional responsibility of the practitioner who is directly treating the patient.
To the extent that the Presentations include information regarding drug dosing, in view of ongoing research, changes in government regulations and the constant flow of information relating to drug therapy and drug reactions, the viewer should not rely on the Presentation content, but rather is urged to check the package insert for each drug for indications, dosage, warnings and precautions.
Some drugs and medical devices presented in the Presentations have United States Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the practitioner to ascertain the FDA status of each drug or device planned for use in their clinical practice.
You shall indemnify, defend and hold harmless CHOP, The Children’s Hospital of Philadelphia Foundation, and its/their current and former employees, officers, and agents, trustees, and their respective successors, heirs and assigns (“Indemnitees”) against any claims, liability, damage, loss or expenses (including attorneys’ fees and expenses of litigation) in connection with any claims, suits, actions, demands or judgments arising directly or indirectly out of your reference to or use of the Presentations.
The Presentations are protected by copyright laws and in some cases patent laws, and all rights are reserved under such laws. No part of the Presentations may be reproduced in any form by any means, or utilized in any other way, absent prior written permission from the copyright owner.
By starting this module, you agree to our Content Disclaimer and Terms of Service.